{"id":472477,"date":"2021-04-07T07:03:26","date_gmt":"2021-04-07T11:03:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=472477"},"modified":"2021-04-07T07:03:26","modified_gmt":"2021-04-07T11:03:26","slug":"applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/","title":{"rendered":"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, April  07, 2021  (GLOBE NEWSWIRE) &#8212; Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentation at the upcoming 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG) taking place April 13-16, 2021. The abstract and presentation include a cross-sectional analysis of nineteen pediatric patients with Classic Galactosemia, characterizing progressive worsening of the central nervous system (CNS) phenotype with age.<\/p>\n<p align=\"justify\">\u201cWe are pleased to share this important data with the medical community,\u201d said\u00a0Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. \u201cThe severity and significant decline in CNS outcomes with age underscores the urgency for a disease-modifying therapy to halt or prevent damage in Galactosemia. \u201d<\/p>\n<p align=\"justify\">\n        <strong>Presentation Details<br \/><\/strong><br \/>\n        <strong>Abstract eP011<\/strong>: Progressive Worsening of Central Nervous System Phenotype in Children with Classic Galactosemia: a Cross-Sectional Analysis<\/p>\n<p align=\"justify\">The poster presentation will be available on the ACMG website.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Applied Therapeutics<br \/><\/strong>Applied Therapeutics\u00a0is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company\u2019s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1\/2 clinical trial in\u00a0June 2019, read out positive top-line biomarker data in adult Galactosemia patients in\u00a0January 2020\u00a0and announced full data from the trial in\u00a0April 2020. A pediatric Galactosemia study commenced in\u00a0June 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in\u00a0September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.<\/p>\n<p>To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N1AvT_E1GTzqlMejTDrRTivfIeg4eSBJmoqFI-IXJ0FgvmOhfK1nJMdSCVG-Wfj8RVeO8ldIdYu4OB5l1YBDMvilicPD1-Cev3UPYxMSmY5nUgC9yNsGW3QulsREriQw\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>www.appliedtherapeutics.com<\/strong><\/a> and follow the company on Twitter <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=igJobheiDgZ81S4xmp-c9GlJOm52fqH1XWRmtnrb8j_BhRDfcRHPbFJwUM96aM-inmNG2FoSa-2-rrKxSaDa5WBG6NxZc0TF__M-IWpfYXA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">@Applied_Tx<\/a><\/strong>.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Maeve Conneighton<br \/>(212) 600-1902 or<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YEvEuQa-r2JnUne_qTgNqlhEm5H0MhteaR3ElJZl5vS-j-ELhm21J2pHwf8MYOsSLupMIP1p5sTlI2hwUL3JcixlzB8dy_hSLOCGvCYc07zBPJV9c852-OOWi26OCXOgK9dJS68uzUuXgCaKBup0kw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">appliedtherapeutics@argotpartners.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E6gktA1g5rG1crVB75455o1tjptRK27jMl48WvEb29R3-yVepn5ZTUUZAnlXvL3iXbR07D9fTQExsi4aOOir5aytXyraLLbWndo58GJnrcleS7-u6j20w8Gv_WSevV9d\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@appliedtherapeutics.com<\/a>\n      <\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/79bb091f-f0ae-4683-a17f-341c2778e14e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) &#8212; Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentation at the upcoming 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG) taking place April 13-16, 2021. The abstract and presentation include a cross-sectional analysis of nineteen pediatric patients with Classic Galactosemia, characterizing progressive worsening of the central nervous system (CNS) phenotype with age. \u201cWe are pleased to share this important data with the medical community,\u201d said\u00a0Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. \u201cThe severity and significant decline in CNS outcomes &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-472477","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) &#8212; Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentation at the upcoming 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG) taking place April 13-16, 2021. The abstract and presentation include a cross-sectional analysis of nineteen pediatric patients with Classic Galactosemia, characterizing progressive worsening of the central nervous system (CNS) phenotype with age. \u201cWe are pleased to share this important data with the medical community,\u201d said\u00a0Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. \u201cThe severity and significant decline in CNS outcomes &hellip; Continue reading &quot;Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-07T11:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics\",\"datePublished\":\"2021-04-07T11:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/\"},\"wordCount\":388,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/\",\"name\":\"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=\",\"datePublished\":\"2021-04-07T11:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/","og_locale":"en_US","og_type":"article","og_title":"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics - Market Newsdesk","og_description":"NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) &#8212; Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster presentation at the upcoming 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG) taking place April 13-16, 2021. The abstract and presentation include a cross-sectional analysis of nineteen pediatric patients with Classic Galactosemia, characterizing progressive worsening of the central nervous system (CNS) phenotype with age. \u201cWe are pleased to share this important data with the medical community,\u201d said\u00a0Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. \u201cThe severity and significant decline in CNS outcomes &hellip; Continue reading \"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-07T11:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics","datePublished":"2021-04-07T11:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/"},"wordCount":388,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/","name":"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=","datePublished":"2021-04-07T11:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjYzOCM0MTA5MDU0IzIxNTY5MDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/applied-therapeutics-to-present-cross-sectional-analysis-of-galactosemia-disease-progression-at-2021-annual-clinical-genetics-meeting-of-the-american-college-of-medical-genetics-and-genomics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/472477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=472477"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/472477\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=472477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=472477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=472477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}